APAC Interstitial Cystitis Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Asia-Pacific interstitial cystitis market is projected to register a substantial CAGR of 12.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

By Severity (Mild to Moderate and Moderate to Severe), Treatment Type (Medications, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, and Others), Mode of Purchase (Over The Counter and Prescription), Patient Type (Pediatric and Adults), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Asia-Pacific interstitial cystitis market are:

Rise in prevalence of interstitial cystitis
Increasing investment in R&D of novel drugs

Market Players:

Some of the major players operating in the Asia-Pacific interstitial cystitis market are:

Alvogen
Sandoz AG
Sun Pharmaceutical Industries Ltd.
Avet Pharmaceuticals Inc.
Viatris Inc.
Pfizer, Inc.
Strides Pharma Science Limited
GlaxoSmithKline plc.
Prestige Consumer Healthcare Inc.
Amneal Pharmaceuticals LLC
Zydus Pharmaceuticals, Inc.
Apotex Inc.
Aurobindo Pharma USA
Dr. Reddy's Laboratories, Inc.
Johnson& Johnson Services, Inc.
Teva Pharmaceuticals, Inc.
Bayer AG
Reckitt Benckiser Group PLC

1 INTRODUCTION 29

1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 OVERVIEW OF ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET 29
1.4 LIMITATIONS 30
1.5 MARKETS COVERED 31

2 MARKET SEGMENTATION 33

2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 CURRENCY AND PRICING 35
2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
2.6 MULTIVARIATE MODELLING 39
2.7 TYPE LIFELINE CURVE 39
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 40
2.9 DBMR MARKET POSITION GRID 41
2.10 MARKET APPLICATION COVERAGE GRID 42
2.11 VENDOR SHARE ANALYSIS 43
2.12 SECONDARY SOURCES 44
2.13 ASSUMPTIONS 44

3 EXECUTIVE SUMMARY 45

4 PREMIUM INSIGHTS 47

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET 50
4.4 EPIDEMIOLOGY 51

5 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: REGULATIONS 52

5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES 52
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES 53
5.3 JAPAN REGULATORY GUIDANCE 54

6 MARKET OVERVIEW 55

6.1 DRIVERS 57
- 6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC) 57
- 6.1.2 RISE IN HEALTHCARE EXPENDITURE 57
- 6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS 58
- 6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY 58
- 6.1.5 RISING DISEASE MANAGEMENT PROGRAMS 58
6.2 RESTRAINTS 59
- 6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS 59
- 6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS 59
- 6.2.3 DEARTH OF SKILLED PROFESSIONALS 60
6.3 OPPORTUNITIES 60
- 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 60
- 6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES 61
- 6.3.3 IMPROVING HEALTHCARE SYSTEM 61
- 6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES 61
6.4 CHALLENGES 62
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 62
- 6.4.2 PATENT EXPIRY OF DRUGS 63

7 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY SEVERITY 64

7.1 OVERVIEW 65
7.2 MILD TO MODERATE 68
7.3 MODERATE TO SEVERE 68

8 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE 69

8.1 OVERVIEW 70
8.2 MEDICATIONS 73
- 8.2.1 ANALGESICS 73
  - 8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 74
    - 8.2.1.1.1 IBUPROFEN 74
    - 8.2.1.1.2 NAPROXEN 74
    - 8.2.1.1.3 OTHERS 74
  - 8.2.1.2 ACETAMINOPHEN 74
  - 8.2.1.3 NON-NARCOTIC PAIN MEDICATION 74
    - 8.2.1.3.1 METHENAMINE 75
    - 8.2.1.3.2 PHENAZOPYRIDINE 75
    - 8.2.1.3.3 OTHERS 75
  - 8.2.1.4 NARCOTIC PAIN MEDICATION 75
    - 8.2.1.4.1 CODEINE 76
    - 8.2.1.4.2 HYDROCODONE 76
    - 8.2.1.4.3 OXYCODONE 76
    - 8.2.1.4.4 OXYMORPHONE 76
    - 8.2.1.4.5 MORPHINE 76
    - 8.2.1.4.6 HYDROMORPHONE 76
    - 8.2.1.4.7 METHADONE 77
    - 8.2.1.4.8 OTHERS 77
- 8.2.2 ANTIHISTAMINES 77
  - 8.2.2.1 LORATADINE 77
  - 8.2.2.2 HYDROXYZINE 77
  - 8.2.2.3 OTHERS 77
- 8.2.3 TRICYCLIC ANTIDEPRESSANTS 77
  - 8.2.3.1 AMITRIPTYLINE 78
  - 8.2.3.2 IMIPRAMINE 78
  - 8.2.3.3 OTHERS 78
- 8.2.4 IMMUNOSUPPRESSANTS 78
  - 8.2.4.1 CYCLOSPORINE 78
  - 8.2.4.2 MYCOPHENOLATE 78
  - 8.2.4.3 OTHERS 79
- 8.2.5 PENTOSAN POLYSULFATE SODIUM 79
- 8.2.6 OTHERS 79
  - 8.2.6.1 ALPHA BLOCKERS 79
    - 8.2.6.1.1 DOXAZOSIN 80
    - 8.2.6.1.2 TERAZOSIN 80
    - 8.2.6.1.3 TAMSULOSIN 80
    - 8.2.6.1.4 OTHERS 80
  - 8.2.6.2 AMPHETAMINES 80
  - 8.2.6.3 LEUKOTRIENE INHIBITORS 80
    - 8.2.6.3.1 MONTELUKAST 81
    - 8.2.6.3.2 ZAFIRLUKAST 81
    - 8.2.6.3.3 OTHERS 81
  - 8.2.6.4 OTHERS 81
8.3 BLADDER INSTILLATIONS 81
- 8.3.1 DIMETHYL SULFOXIDE 82
- 8.3.2 HEPARIN 82
- 8.3.3 OTHERS 82
8.4 BOTULINUM TOXIN A 82
8.5 SURGERY 83
- 8.5.1 FULGURATION 83
- 8.5.2 RESECTION 83
- 8.5.3 BLADDER AUGMENTATION 83
8.6 NERVE STIMULATIONS 83

9 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION 85

9.1 OVERVIEW 86
9.2 ORAL 89
- 9.2.1 TABLETS 89
  - 9.2.1.1 EXTENDED RELEASE 90
  - 9.2.1.2 IMMEDIATE RELEASE 90
- 9.2.2 CAPSULES 90
- 9.2.3 OTHERS 90
9.3 PARENTERAL 90
9.4 INTRAVESICAL 91
9.5 TOPICAL 91
9.6 OTHERS 92

10 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE 93

10.1 OVERVIEW 94
10.2 OVER THE COUNTER 97
10.3 PRESCRIPTION 97

11 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE 98

11.1 OVERVIEW 99
11.2 ADULTS 102
11.3 PEDIATRIC 102

12 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY END USER 103

12.1 OVERVIEW 104
12.2 HOSPITALS 107
12.3 CLINICS 107
12.4 HOME HEALTHCARE 108
12.5 OTHERS 108

13 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL 109

13.1 OVERVIEW 110
13.2 DIRECT TENDER 113
13.3 RETAIL SALES 113
- 13.3.1 PHARMACY STORES 114
- 13.3.2 ONLINE RETAIL CHANNEL 114
- 13.3.3 OTHERS 114
13.4 OTHERS 114

14 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY 115

14.1 ASIA-PACIFIC 116
- 14.1.1 CHINA 127
- 14.1.2 JAPAN 133
- 14.1.3 INDIA 139
- 14.1.4 AUSTRALIA 145
- 14.1.5 SOUTH KOREA 151
- 14.1.6 THAILAND 157
- 14.1.7 SINGAPORE 163
- 14.1.8 INDONESIA 169
- 14.1.9 MALAYSIA 175
- 14.1.10 VIETNAM 181
- 14.1.11 PHILIPPINES 187
- 14.1.12 REST OF ASIA-PACIFIC 193

15 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE 194

15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 194

16 SWOT ANALYSIS 195

17 COMPANY PROFILE 196

17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD. 196
- 17.1.1 COMPANY SNAPSHOT 196
- 17.1.2 REVENUE ANALYSIS 196
- 17.1.3 PRODUCT PORTFOLIO 197
- 17.1.4 RECENT DEVELOPMENTS 197
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 198
- 17.2.1 COMPANY SNAPSHOT 198
- 17.2.2 REVENUE ANALYSIS 198
- 17.2.3 COMPANY SHARE ANALYSIS 199
- 17.2.4 PRODUCT PORTFOLIO 199
- 17.2.5 RECENT DEVELOPMENT 199
17.3 HIKMA PHARMACEUTICALS PLC 200
- 17.3.1 COMPANY SNAPSHOT 200
- 17.3.2 REVENUE ANALYSIS 200
- 17.3.3 COMPANY SHARE ANALYSIS 201
- 17.3.4 PRODUCT PORTFOLIO 201
- 17.3.5 RECENT DEVELOPMENTS 201
17.4 DR. REDDY'S LABORATORIES LTD 202
- 17.4.1 COMPANY SNAPSHOT 202
- 17.4.2 REVENUE ANALYSIS 202
- 17.4.3 COMPANY SHARE ANALYSIS 203
- 17.4.4 PRODUCT PORTFOLIO 203
- 17.4.5 RECENT DEVELOPMENT 204
17.5 BAYER AG 205
- 17.5.1 COMPANY SNAPSHOT 205
- 17.5.2 REVENUE ANALYSIS 205
- 17.5.3 COMPANY SHARE ANALYSIS 206
- 17.5.4 PRODUCT PORTFOLIO 206
- 17.5.5 RECENT DEVELOPMENT 206
17.6 AMNEAL PHARMACEUTICAL LLC. 207
- 17.6.1 COMPANY SNAPSHOT 207
- 17.6.2 REVENUE ANALYSIS 207
- 17.6.3 PRODUCT PORTFOLIO 208
- 17.6.4 RECENT DEVELOPMENTS 208
17.7 APOTEX 209
- 17.7.1 COMPANY SNAPSHOT 209
- 17.7.2 PRODUCT PORTFOLIO 209
- 17.7.3 RECENT DEVELOPMENT 209
17.8 AUROBINDO PHARMA USA 210
- 17.8.1 COMPANY SNAPSHOT 210
- 17.8.2 REVENUE ANALYSIS 210
- 17.8.3 PRODUCT PORTFOLIO 211
- 17.8.4 RECENT DEVELOPMENT 211
17.9 AVET PHARMACEUTICALS INC. 212
- 17.9.1 COMPANY SNAPSHOT 212
- 17.9.2 PRODUCT PORTFOLIO 212
- 17.9.3 RECENT DEVELOPMENT 212
17.10 ALVOGEN 213
- 17.10.1 COMPANY SNAPSHOT 213
- 17.10.2 PRODUCT PORTFOLIO 213
- 17.10.3 10.3RECENT DEVELOPMENT 213
17.11 ACCORD-UK LTD 214
- 17.11.1 COMPANY SNAPSHOT 214
- 17.11.2 PRODUCT PORTFOLIO 214
- 17.11.3 11.3RECENT DEVELOPMENT 214
17.12 GLAXOSMITHKLINE PLC 215
- 17.12.1 COMPANY SNAPSHOT 215
- 17.12.2 12.2REVENUE ANALYSIS 215
- 17.12.3 PRODUCT PORTFOLIO 216
- 17.12.4 RECENT DEVELOPMENT 216
17.13 JOHNSON & JOHNSON SERVICES, INC. 217
- 17.13.1 COMPANY SNAPSHOT 217
- 17.13.2 REVENUE ANALYSIS 217
- 17.13.3 PRODUCT PORTFOLIO 218
- 17.13.4 RECENT DEVELOPMENT 218
17.14 LANNETT 219
- 17.14.1 COMPANY SNAPSHOT 219
- 17.14.2 REVENUE ANALYSIS 219
- 17.14.3 PRODUCT PORTFOLIO 220
- 17.14.4 RECENT DEVELOPMENT 220
17.15 PRESTIGE CONSUMER HEALTHCARE 221
- 17.15.1 COMPANY SNAPSHOT 221
- 17.15.2 REVENUE ANALYSIS 221
- 17.15.3 PRODUCT PORTFOLIO 222
- 17.15.4 RECENT DEVELOPMENTS 222
17.16 PFIZER INC. 223
- 17.16.1 COMPANY SNAPSHOT 223
- 17.16.2 REVENUE ANALYSIS 223
- 17.16.3 PRODUCT PORTFOLIO 224
- 17.16.4 RECENT DEVELOPMENT 224
17.17 RECKITT BENCKISER GROUP PLC. 225
- 17.17.1 COMPANY SNAPSHOT 225
- 17.17.2 REVENUE ANALYSIS 225
- 17.17.3 PRODUCT PORTFOLIO 225
- 17.17.4 RECENT DEVELOPMENT 226
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 227
- 17.18.1 COMPANY SNAPSHOT 227
- 17.18.2 REVENUE ANALYSIS 227
- 17.18.3 PRODUCT PORTFOLIO 228
- 17.18.4 RECENT DEVELOPMENT 228
17.19 STRIDES PHARMA SCIENCE LIMITED. 229
- 17.19.1 COMPANY SNAPSHOT 229
- 17.19.2 REVENUE ANALYSIS 229
- 17.19.3 PRODUCT PORTFOLIO 230
- 17.19.4 RECENT DEVELOPMENT 230
17.20 VIATRIS INC. 231
- 17.20.1 COMPANY SNAPSHOT 231
- 17.20.2 REVENUE ANALYSIS 231
- 17.20.3 PRODUCT PORTFOLIO 232
- 17.20.4 RECENT DEVELOPMENT 232
17.21 VISTA PHARM INC. 233
- 17.21.1 COMPANY SNAPSHOT 233
- 17.21.2 PRODUCT PORTFOLIO 233
- 17.21.3 RECENT DEVELOPMENTS 233
17.22 ZYDUS PHARMACEUTICALS INC., 234
- 17.22.1 COMPANY SNAPSHOT 234
- 17.22.2 REVENUE ANALYSIS 234
- 17.22.3 PRODUCT PORTFOLIO 235
- 17.22.4 RECENT DEVELOPMENTS 235

18 QUESTIONNAIRE 236

19 RELATED REPORTS 239

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 33
FIGURE 2 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION 36
FIGURE 3 ASIA PACIFIC BLADDER DISORDERS MARKET: DROC ANALYSIS 37
FIGURE 4 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 38
FIGURE 5 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS 38
FIGURE 6 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS 40
FIGURE 7 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID 41
FIGURE 8 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID 42
FIGURE 9 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS 43
FIGURE 10 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 46
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 47
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029 47
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET 56
FIGURE 14 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021 65
FIGURE 15 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION) 66
FIGURE 16 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029) 66
FIGURE 17 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE 67
FIGURE 18 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021 70
FIGURE 19 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION) 71
FIGURE 20 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029) 71
FIGURE 21 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 72
FIGURE 22 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 86
FIGURE 23 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 87
FIGURE 24 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 87
FIGURE 25 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 88
FIGURE 26 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021 94
FIGURE 27 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 95
FIGURE 28 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 95
FIGURE 29 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 96
FIGURE 30 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021 99
FIGURE 31 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 100
FIGURE 32 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029) 100
FIGURE 33 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE 101
FIGURE 34 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021 104
FIGURE 35 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION) 105
FIGURE 36 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029) 105
FIGURE 37 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE 106
FIGURE 38 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021 110
FIGURE 39 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 111
FIGURE 40 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 111
FIGURE 41 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 112
FIGURE 42 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 117
FIGURE 43 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 119
FIGURE 44 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 119
FIGURE 45 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 120
FIGURE 46 ASIA-PACIFIC INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 120
FIGURE 47 ASIA PACIFIC INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 194